Evotec (ETR:EVT) Trading Down 4.6%

Shares of Evotec SE (ETR:EVTGet Rating) fell 4.6% during mid-day trading on Wednesday . The company traded as low as €18.29 ($18.66) and last traded at €18.80 ($19.18). 953,719 shares were traded during trading, a decline of 30% from the average session volume of 1,360,000 shares. The stock had previously closed at €19.70 ($20.10).

Analyst Ratings Changes

A number of brokerages have recently issued reports on EVT. Warburg Research set a €38.00 ($38.78) target price on Evotec in a research note on Thursday, August 11th. Morgan Stanley set a €32.00 ($32.65) target price on Evotec in a research note on Wednesday, August 10th. Royal Bank of Canada set a €35.00 ($35.71) target price on Evotec in a research note on Tuesday, August 23rd. Berenberg Bank set a €47.00 ($47.96) target price on Evotec in a research note on Wednesday, June 29th. Finally, Deutsche Bank Aktiengesellschaft set a €30.00 ($30.61) target price on Evotec in a research note on Wednesday, August 31st.

Evotec Stock Down 3.8 %

The stock has a market capitalization of $3.18 billion and a PE ratio of 449.25. The firm has a 50 day moving average of €24.25 and a two-hundred day moving average of €24.79. The company has a current ratio of 3.57, a quick ratio of 3.24 and a debt-to-equity ratio of 37.88.

About Evotec

(Get Rating)

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications of diabetes, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health.

Recommended Stories

Receive News & Ratings for Evotec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evotec and related companies with MarketBeat.com's FREE daily email newsletter.